組織診断市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、技術別、地域別、競合別、2020～2030年

組織診断の世界市場規模は2024年に57億2,000万米ドルで、2030年までのCAGRは8.54%で93億7,000万米ドルに達すると予測されています。

組織診断の世界市場は、ヘルスケア診断の広範な分野における重要なセグメントです。この市場には、疾患、特にがんの検出、診断、モニタリングのために組織や細胞を検査するために使用される幅広い技術や手法が含まれます。同市場は、世界のがん罹患率の上昇、高齢化人口の増加、正確で個別化された医療への需要の高まりなど、いくつかの主要な要因によって牽引されています。組織診断技術には、免疫組織化学、in situハイブリダイゼーション、デジタル病理学、特殊染色などが含まれます。これらのツールは、病理医やヘルスケア専門家が疾患マーカーを特定し、組織異常を評価し、患者に最も適した治療戦略を決定する際に役立ちます。さらに、組織診断における人工知能（AI）と機械学習の統合は、解析の精度と効率を高め、より迅速で正確な疾患の検出と分類を可能にしています。カリフォルニア大学サンフランシスコ校とミシガン大学が2024年に主導した研究によると、AIを搭載した診断ツールは、神経外科医が隠れたがん組織を検出するのを助け、悪性度の高い腫瘍の再発を遅らせたり、悪性度の低い腫瘍の再発を予防したりする可能性があります。FastGliomaというツールは、生検から数秒以内にリアルタイムで正確な診断情報を提供します。まだFDAの承認待ちではあるが、FastGliomaを使用した患者の3.8％しか高リスク組織が残っていなかったのに対し、使用しなかった患者では24％でした。この技術は、乳がんや前立腺がんを含む他のがんについても試験される可能性があります。

北米は医療費の高騰と先端技術の導入により、従来から有力な市場であったが、アジア太平洋の新興国も、ヘルスケアインフラの拡大と意識の高まりにより、大幅な成長を遂げています。組織診断市場は、診断精度の向上、アプリケーションの拡大、患者ケアの最適化を目指した研究開発の継続的な取り組みによって進化を続けており、世界的に現代医療システムの重要な構成要素となっています。

市場促進要因

がん罹患率の増加

技術の進歩

ヘルスケア支出の増加

意識向上と検診プログラム

主な市場課題

機器の高コスト

開発途上地域でのアクセス制限

主な市場動向

デジタル病理学とAIの統合

テレパソロジーの需要拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の組織診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（機器、試薬、消耗品）
  • 用途別（乳がん、前立腺がん、胃がん、その他のがん）
  • 技術別（免疫組織化学、in-situハイブリダイゼーション、デジタル病理学およびワークフロー管理、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の組織診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • メキシコ
  • カナダ

第7章 欧州の組織診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の組織診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の組織診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの組織診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Nanoscribe GmbH & Co. KG
• Stratasys Ltd.
• 3D Systems Inc.
• EOS GmbH
• Renishaw PLC
• Exone Company.
• Formlabs Inc.,
• Materialise NV.
• SLM Solutions Group AG
• Oxferd Performance Materials, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Tissue Diagnostics Market was valued at USD 5.72 billion in 2024 and is anticipated to reach USD 9.37 billion with a CAGR of 8.54% through 2030. The Global Tissue Diagnostics Market represents a critical segment within the broader field of healthcare diagnostics. It encompasses a wide range of techniques and technologies used to examine tissues and cells for the detection, diagnosis, and monitoring of diseases, particularly cancer. The market is driven by several key factors, including the rising incidence of cancer worldwide, the growing aging population, and the increasing demand for precise and personalized medicine. Tissue diagnostics techniques include immunohistochemistry, in situ hybridization, digital pathology, and special staining, among others. These tools aid pathologists and healthcare professionals in identifying disease markers, evaluating tissue abnormalities, and determining the most appropriate treatment strategies for patients. Furthermore, the integration of artificial intelligence (AI) and machine learning in tissue diagnostics is enhancing the accuracy and efficiency of analysis, enabling faster and more accurate disease detection and classification. A study led by UC San Francisco and the University of Michigan in 2024, shows that an AI-powered diagnostic tool helps neurosurgeons detect hidden cancerous tissue, potentially delaying the recurrence of high-grade tumors and preventing it in lower-grade ones. The tool, FastGlioma, provides real-time, accurate diagnostic information within seconds of a biopsy. While it's still awaiting FDA approval, the study found that only 3.8% of patients using FastGlioma had remaining high-risk tissue, compared to 24% in those who did not. The technique may also be tested for other cancers, including breast and prostate.

While North America has traditionally been a prominent market due to high healthcare expenditures and advanced technology adoption, emerging economies in Asia-Pacific are also witnessing substantial growth, driven by expanding healthcare infrastructure and increasing awareness. The tissue diagnostics market continues to evolve, with ongoing research and development efforts aimed at improving diagnostic accuracy, expanding applications, and optimizing patient care, making it a vital component of modern healthcare systems globally.

Key Market Drivers

Increasing Cancer Incidence

The increasing cancer incidence is a significant driver in the Global Tissue Diagnostics Market. Cancer has become a pressing global health concern, with rising incidence rates observed across the world. The International Agency for Research on Cancer (IARC) has provided updated estimates for global cancer statistics by region for the year 2022. The data indicates nearly 20 million new cancer cases (including nonmelanoma skin cancers [NMSCs]) and 9.7 million cancer-related deaths (also including NMSC). These figures suggest that approximately one in five individuals, regardless of gender, will be diagnosed with cancer during their lifetime, while one in nine men and one in twelve women will succumb to the disease.

This surge in cancer cases underscores the critical role of tissue diagnostics in disease detection, characterization, and treatment planning. Tissue diagnostics techniques, such as histopathology and immunohistochemistry, are fundamental in confirming cancer diagnoses, determining cancer type and stage, and assessing the aggressiveness of the disease. As cancer rates continue to climb due to factors like lifestyle changes, aging populations, environmental factors, and genetic predisposition, the demand for tissue diagnostics escalates in parallel. Moreover, advancements in tissue-based molecular testing have enabled the identification of specific biomarkers that guide targeted therapies, further emphasizing the importance of tissue diagnostics in cancer treatment. The ongoing battle against cancer necessitates accurate and timely tissue analysis, making tissue diagnostics an indispensable tool in the fight against this widespread and complex disease. As a result, the tissue diagnostics market is poised for sustained growth, driven by the ever-increasing demand for effective cancer diagnosis and management on a global scale.

Advancements in Technology

Advancements in technology have played a pivotal role in driving innovation and growth in the Global Tissue Diagnostics Market. These technological developments have significantly enhanced the precision, efficiency, and accessibility of tissue diagnostics, making them more indispensable than ever in the field of healthcare. Digital pathology is one such advancement, allowing for the digitization of histopathological slides, enabling remote access, and facilitating collaborative consultations among pathologists. Artificial intelligence (AI) and machine learning have also emerged as game-changers, automating image analysis, improving diagnostic accuracy, and helping identify subtle patterns and biomarkers that might be missed by the human eye. For instance, In June 2022, F. Hoffmann La Roche announced the CE launch of the next-generation VENTANA DP 600 slide scanner. This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, which provides ease of use and workflow flexibility for the pathology lab.

Furthermore, the integration of molecular techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS) into tissue diagnostics enables the detection of specific genetic mutations, gene expression profiles, and protein markers, aiding in precise disease characterization and personalized treatment decisions. These technological strides have not only expedited the diagnostic process but have also paved the way for more comprehensive and tailored patient care. As technology continues to evolve, tissue diagnostics are likely to become even more sophisticated and integral to the diagnosis and management of a wide range of diseases, further advancing the global tissue diagnostics market.

Increasing Healthcare Expenditure

The increasing healthcare expenditure is a significant factor influencing the growth of the Global Tissue Diagnostics Market. Globally, governments, healthcare institutions, and individuals are dedicating a larger portion of their financial resources to healthcare services and technologies. This surge in healthcare spending reflects the growing awareness of the importance of early disease detection and precise diagnostics, particularly in the context of complex diseases like cancer. Tissue diagnostics, which play a pivotal role in disease diagnosis, staging, and treatment planning, are beneficiaries of this increased expenditure. As healthcare budgets expand, healthcare providers can invest in advanced tissue diagnostic equipment, cutting-edge technologies, and skilled personnel, ensuring better accessibility and higher quality diagnostic services. Moreover, with greater financial resources allocated to research and development in the healthcare sector, there is ongoing innovation in tissue diagnostics, leading to the development of more accurate and efficient diagnostic tests and techniques. The increasing healthcare expenditure is, therefore, not only driving the demand for tissue diagnostics but also fostering an environment of continuous improvement and innovation in this crucial segment of the healthcare industry, ultimately benefiting patients through earlier, more accurate, and more effective disease management.

Awareness and Screening Programs

Awareness and screening programs play a vital role in shaping the Global Tissue Diagnostics Market. These initiatives are designed to raise public consciousness about the importance of early disease detection and encourage individuals to undergo regular health screenings. In particular, awareness campaigns and organized screening programs for diseases such as cancer, including breast, cervical, colorectal, and prostate cancers, have been instrumental in driving the demand for tissue diagnostics. For instance, In March 2021, The Quick-Core Auto Biopsy System ("Quick-Core Auto") for soft tissue biopsy was launched by IZI Medical Products LLC ("IZI"), a prominent developer of medical devices used in interventional radiology and interventional oncology treatments. The Quick-Core Auto is a lightweight, automatic biopsy equipment that adds to the reliability, precision, and quality of IZI's Quick-Core semi-automatic biopsy system.

As these programs emphasize the benefits of early diagnosis, more individuals seek medical attention, resulting in an increased volume of tissue samples requiring analysis. Tissue diagnostics, including techniques like histopathology and immunohistochemistry, are critical components of these screening programs, as they confirm diagnoses, provide valuable insights into disease progression, and guide appropriate treatment strategies. The success of these programs is further bolstered by technological advancements in tissue diagnostics, which enhance accuracy and speed in disease detection. By fostering a culture of proactive health management and early intervention, awareness and screening programs contribute significantly to the growth of the tissue diagnostics market, ensuring that diseases are identified and managed at their earliest, most treatable stages, ultimately improving patient outcomes and reducing the burden of advanced diseases on healthcare systems worldwide.

Key Market Challenges

High Cost of Equipment

The high cost of equipment is a significant restraining factor in the Global Tissue Diagnostics Market. Tissue diagnostic technologies, including advanced imaging systems, digital pathology scanners, molecular testing platforms, and automated tissue processors, often come with a substantial price tag. The initial capital investment required to acquire and install these machines can strain the budgets of healthcare institutions, particularly smaller clinics and facilities in resource-constrained regions. Moreover, the ongoing maintenance and service costs can add to the financial burden. This cost factor can deter healthcare providers from adopting or upgrading tissue diagnostic equipment, leading to outdated infrastructure that hampers diagnostic accuracy and efficiency. In addition, the affordability of tissue diagnostic services for patients can be compromised when healthcare providers pass on the high equipment costs through service fees. Addressing the high cost of equipment is essential to ensure equitable access to tissue diagnostics globally. Efforts to reduce costs, such as the development of more cost-effective diagnostic platforms and public-private partnerships, are crucial in making tissue diagnostics more accessible to healthcare providers and patients alike, thereby overcoming this significant restraint in the market.

Limited Accessibility in Developing Regions

Limited accessibility in developing regions is a significant challenge facing the Global Tissue Diagnostics Market. In many low-resource and underserved areas of developing countries, access to tissue diagnostics is constrained by various factors. Firstly, there is a shortage of well-equipped healthcare facilities with the necessary infrastructure and skilled personnel to perform tissue diagnostics accurately. Secondly, the high cost of diagnostic equipment, reagents, and maintenance can be prohibitive for healthcare institutions with limited budgets. Thirdly, geographical barriers and inadequate transportation infrastructure can impede patients' ability to reach healthcare centers that offer tissue diagnostic services, especially in remote rural areas. Additionally, a lack of awareness and education about the importance of early disease detection can lead to delayed healthcare-seeking behavior. Addressing limited accessibility in developing regions requires multifaceted efforts, including investments in healthcare infrastructure, training programs to build a skilled workforce, development of affordable and portable diagnostic technologies, and public health campaigns to raise awareness and encourage regular screenings. Overcoming these accessibility challenges is essential for ensuring that individuals in underserved regions have equitable access to tissue diagnostics, leading to earlier disease detection and improved healthcare outcomes.

Key Market Trends

Digital Pathology and AI Integration

Digital Pathology and AI Integration is a transformative trend in the Global Tissue Diagnostics Market. Digital pathology involves the digitization of traditional glass slides, enabling pathologists and healthcare professionals to view and analyze high-resolution histopathological images electronically. This shift from traditional microscopy to digital platforms allows for remote access, streamlined collaborations, and the creation of vast image archives. Moreover, the integration of artificial intelligence (AI) and machine learning algorithms enhances the diagnostic capabilities of digital pathology.

AI-powered image analysis software can assist pathologists in identifying and quantifying tissue abnormalities, identifying specific biomarkers, and even predicting disease outcomes. These technologies improve diagnostic accuracy, reduce the risk of human error, and enable faster turnaround times, ultimately leading to more efficient and precise tissue diagnostics. Furthermore, AI-driven predictive analytics can help pathologists make more informed treatment recommendations by considering vast datasets and identifying subtle patterns that might be missed by the human eye. As the adoption of digital pathology and AI continues to grow, it not only enhances the quality of tissue diagnostics but also facilitates the development of large-scale databases for research and the delivery of pathology services to underserved areas through telepathology, making it a pivotal trend in advancing the field of tissue diagnostics.

Growing Telepathology demand

Telepathology is a crucial trend in the Global Tissue Diagnostics Market, revolutionizing the way pathology services are delivered and accessed. This approach involves the remote consultation and interpretation of pathology specimens, primarily histopathological images, by pathologists located at a distance from the patient or the specimen source. Telepathology leverages digital technology and high-speed internet connectivity to transmit high-resolution images, clinical data, and patient histories to remote pathologists for analysis. This trend offers several significant advantages, including improved access to specialized expertise and consultations regardless of geographical boundaries. It enhances collaboration among pathologists and facilitates second opinions on complex cases, ultimately leading to more accurate diagnoses and treatment decisions. Additionally, telepathology has proven particularly valuable in underserved and remote regions where access to experienced pathologists may be limited. It also supports healthcare systems in managing workloads efficiently by enabling pathologists to review cases remotely, thereby reducing turnaround times and enhancing overall patient care. As the demand for pathology services continues to grow, telepathology plays a pivotal role in addressing challenges related to access, expertise, and timely diagnosis, making it a transformative trend in the field of tissue diagnostics.

Segmental Insights

Product Insights

In the Global Tissue Diagnostics Market, the Reagents and Consumables segment is poised to be the fastest-growing due to several compelling factors. The continuous need for replenishment and their essential role in daily laboratory operations ensure sustained demand. As tissue-based diagnostic tests like immunohistochemistry (IHC), in situ hybridization (ISH), and hematoxylin and eosin (H&E) staining become increasingly critical, the consumption of reagents and consumables grows rapidly.

The rise in the prevalence of cancer and chronic diseases is driving more frequent diagnostic testing, which directly fuels the demand for these consumables. Furthermore, advancements in precision medicine and personalized healthcare are pushing laboratories to adopt more specialized reagents, enhancing diagnostic accuracy and efficiency. The growing trend of automation in pathology labs also plays a significant role in this expansion, as automated platforms require specific consumables to ensure seamless operation.

Additionally, increasing regulatory requirements and the global emphasis on high-quality diagnostic practices are further accelerating the adoption of reagents and consumables. With the ongoing expansion of diagnostic facilities in emerging markets and a greater focus on early disease detection, the Reagents and Consumables segment is set to experience rapid growth, making it the fastest-growing segment in the global tissue diagnostics market..

Application Insights

Based on the Application segment, In the Global Tissue Diagnostics Market, breast cancer was the dominating segment among breast cancer, prostate cancer, and gastric cancer. This dominance is primarily driven by the high global prevalence and incidence rates of breast cancer, making it one of the most commonly diagnosed cancers worldwide. The rising awareness and initiatives promoting early detection and screening programs have further contributed to the increasing demand for tissue diagnostic solutions for breast cancer. Advancements in diagnostic techniques, such as immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology, have enhanced the accuracy and efficiency of breast cancer diagnosis. These methods are crucial for detecting hormone receptor status, such as estrogen and progesterone receptors, and HER2/neu status, which are essential for determining targeted treatment options. The growing adoption of personalized medicine and targeted therapies has further fueled the need for precise tissue-based diagnostics. Moreover, breast cancer screening programs are widely implemented in both developed and developing countries, supported by government and non-governmental organizations, driving the routine use of tissue diagnostics. The availability of comprehensive testing options, coupled with technological advancements in automation and multiplex assays, has enhanced diagnostic capabilities, further strengthening this segment's position.

Regional Insights

North America was the dominating region in the Global Tissue Diagnostics Market, driven by several key factors, including a well-established healthcare infrastructure, high cancer prevalence, and widespread adoption of advanced diagnostic technologies. The region benefits from a strong presence of leading market players, such as Roche Diagnostics, Danaher Corporation, and Thermo Fisher Scientific, which continuously invest in research and development to introduce innovative tissue diagnostic solutions. The rising incidence of cancer, particularly breast, lung, and colorectal cancers, has significantly increased the demand for tissue-based diagnostics in North America. According to the American Cancer Society, millions of new cancer cases are diagnosed annually in the U.S., fueling the need for accurate and early diagnostic solutions. Additionally, government initiatives and funding programs aimed at cancer research and early detection screening programs further support market growth. Technological advancements, such as digital pathology, artificial intelligence-driven diagnostics, and automation, have gained rapid traction in the region. North America's strong regulatory framework, including approvals from agencies like the U.S. Food and Drug Administration (FDA), ensures the adoption of high-quality and reliable diagnostic tests. Moreover, the presence of well-trained healthcare professionals and the availability of comprehensive reimbursement policies facilitate the widespread adoption of tissue diagnostics in hospitals, diagnostic laboratories, and research institutions.

Key Market Players

• Nanoscribe GmbH & Co. KG
• Stratasys Ltd.
• 3D Systems Inc.
• EOS GmbH
• Renishaw PLC
• Exone Company.
• Formlabs Inc.,
• Materialise NV.
• SLM Solutions Group AG
• Oxferd Performance Materials, Inc.

Report Scope:

In this report, the Global Tissue Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Diagnostics Market, By Product:

• Instruments
• Reagents and Consumables

Tissue Diagnostics Market, By Application:

• Breast Cancer
• Prostate Cancer
• Gastric Cancer
• Other Cancers

Tissue Diagnostics Market, By Technology:

• Immunohistochemistry
• In-Situ Hybridizations
• Digital Pathology and Workflow Management
• Others

Tissue Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Diagnostics Market.

Available Customizations:

Global Tissue Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Tissue Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents and Consumables)
  • 5.2.2. By Application (Breast Cancer, Prostate Cancer, Gastric Cancer, Other Cancers)
  • 5.2.3. By Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology and Workflow Management, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Tissue Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tissue Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
  • 6.3.2. Mexico Tissue Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
  • 6.3.3. Canada Tissue Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology

7. Europe Tissue Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Tissue Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
  • 7.3.2. Germany Tissue Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
  • 7.3.3. United Kingdom Tissue Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
  • 7.3.4. Italy Tissue Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
  • 7.3.5. Spain Tissue Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology

8. Asia-Pacific Tissue Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Tissue Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
  • 8.3.2. India Tissue Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
  • 8.3.3. South Korea Tissue Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
  • 8.3.4. Japan Tissue Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
  • 8.3.5. Australia Tissue Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology

9. South America Tissue Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tissue Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
  • 9.3.2. Argentina Tissue Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
  • 9.3.3. Colombia Tissue Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology

10. Middle East and Africa Tissue Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tissue Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
  • 10.3.2. Saudi Arabia Tissue Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
  • 10.3.3. UAE Tissue Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Nanoscribe GmbH & Co. KG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Stratasys Ltd.
• 14.3. 3D Systems Inc.
• 14.4. EOS GmbH
• 14.5. Renishaw PLC
• 14.6. Exone Company.
• 14.7. Formlabs Inc.,
• 14.8. Materialise NV.
• 14.9. SLM Solutions Group AG
• 14.10. Oxferd Performance Materials, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer